Graphical abstract

No abstract

No abstract

Andrographolide (AG) is a diterpenoid lactone found in Andrographis paniculata leaves and stems. It has excellent activity against various cancer cells, for example, skin cancer cells. However, application of AG for skin cancer treatment in clinical trials is limited due to its poor water solubility. To overcome this problem, oil in water AG-loaded nanoemulsion (AG-NE) would be prepared. The objectives of this study were to investigate physicochemical properties of AG-NE and to determine its activity against non-melanoma skin cancer cells. Nanoemulsion (NE) without AG (NE base) and NE containing AG (0.1%w/w) were prepared by high-pressure homogenization technique. They contained a mixture of Tween 80 and Span 80 (5:1) (10% w/w) as an emulsifier. Their droplet size, zeta potential and physical stability were evaluated. Cytotoxicity of AG and AG-NE to non-melanoma skin cancer cells (A-431 cells) and normal skin fibroblast cells (HFF-1 cells) were investigated. The results showed that NE base and AG-NE had droplet size in a nanometer range. They had low viscosity with the flow behavior consistent with Newtonian liquids. Although their zeta potential values were slightly low, they showed good physical stability against centrifugal force. AG and AG-NE were not toxic to HFF-1 cells, but they could induce apoptosis of A-431 cells with IC50 of 25.83 μg/ml and 58.32 mg/ml, respectively. Therefore, AG-NE has become possible to use for investigation of its efficacy and safety in animal models and clinical trials.

T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy. Their remarkable antitumor effect has exerted complete remission in treating B-cell malignancies. Although successful patient treatment has been shown, improvement to the structure of CAR to enhance its safety and efficacy profile is warranted. Transduction with a lentiviral vector (LVV) leading to the expression of CARs is also a critical step in redirecting T cells to target specific tumor antigens. To improve the efficacy of CD19 CARs in this study, the transduction ability of second and third generations LVV were compared. Ex vivo expansion of CD19 CARs T cells from healthy donors’ peripheral blood mononuclear cells was performed after transduction of T cells with second and third generations LVV. Transduction efficacy of transduced T cells was determined to show a higher percentage in the third generations LVV transduced cells, with no changes in viability and identity of cells characterized by immunophenotyping. Testing the cytotoxic capacity of third generations LVV-transduced T cells against target cells showed higher reactivity against control cells. Cytokine expression was detected on the CD19 CARs T cells, suggesting that these cells limit in vitro growth of B-cell leukemia via secretion of the pro-inflammatory cytokine IFN γ. To investigate whether the third generation LVV transduced T cells can limit CD19 lymphoma growth in vivo, an analysis of tumor burden in a mouse model assessed by bioluminescence imaging was performed. We found that, in the presence of CD19 CARs T cells, the level of tumor burden was markedly reduced. In addition, an increase in the length of survival in mice receiving CAR-CD19 T cells was also observed. This suggests that transduction with third generations LVV generate a functional CAR-CD19 T cells, which may provide a safer and effective therapy for B-cell malignancies.